Brokerages Set Catalent Inc (NYSE:CTLT) Target Price at $56.29

Catalent Inc (NYSE:CTLT) has been assigned an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $56.29.

A number of analysts have recently weighed in on CTLT shares. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group upped their price target on shares of Catalent to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Morgan Stanley upped their price target on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 28th. Jefferies Financial Group raised shares of Catalent from a “hold” rating to a “buy” rating and upped their price target for the stock from $50.00 to $62.00 in a research note on Friday, June 21st. Finally, Robert W. Baird upped their price target on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th.

Catalent stock traded up $0.44 during midday trading on Wednesday, reaching $48.14. 23,000 shares of the stock traded hands, compared to its average volume of 823,152. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 1.71. The firm has a fifty day moving average price of $51.29 and a two-hundred day moving average price of $49.30. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of 29.68, a PEG ratio of 2.40 and a beta of 1.70. Catalent has a fifty-two week low of $29.23 and a fifty-two week high of $58.38.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, August 27th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.03. The firm had revenue of $725.70 million during the quarter, compared to analyst estimates of $719.20 million. Catalent had a net margin of 5.46% and a return on equity of 15.89%. Catalent’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 EPS. Analysts anticipate that Catalent will post 1.82 earnings per share for the current year.

In other news, SVP Steven L. Fasman sold 4,053 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total transaction of $219,024.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO John R. Chiminski sold 97,043 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $48.84, for a total transaction of $4,739,580.12. The disclosure for this sale can be found here. Insiders have sold 117,036 shares of company stock worth $5,811,872 in the last 90 days. 1.30% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in CTLT. Evolution Wealth Advisors LLC acquired a new position in Catalent in the 2nd quarter valued at approximately $32,000. Advisory Services Network LLC increased its stake in Catalent by 115.5% in the 2nd quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares during the period. Zions Bancorporation N.A. acquired a new position in Catalent in the 1st quarter valued at approximately $61,000. Bamco Inc. NY acquired a new position in Catalent in the 2nd quarter valued at approximately $81,000. Finally, Point72 Hong Kong Ltd acquired a new position in Catalent in the 2nd quarter valued at approximately $165,000.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: What is the NASDAQ?

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.